A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
Public ClinicalTrials.gov record NCT06843447. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Have Relapsed After Prior Platinum-based Chemotherapy
Study identification
- NCT ID
- NCT06843447
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 460 participants
Conditions and interventions
Conditions
Interventions
- Bevacizumab Biological
- Carboplatin Drug
- Gemcitabine Drug
- Paclitaxel Drug
- Pegylated liposomal doxorubicin Drug
- Pembrolizumab Biological
- Raludotatug Deruxtecan Biological
- Rescue Medication Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 14, 2025
- Primary completion
- Mar 26, 2029
- Completion
- Mar 26, 2029
- Last update posted
- May 12, 2026
2025 – 2029
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University of Louisville, James Graham Brown Cancer Center ( Site 0009) | Louisville | Kentucky | 40202 | Recruiting |
| Memorial Sloan Kettering Cancer Center ( Site 0003) | New York | New York | 10065 | Recruiting |
| Houston Methodist Hospital ( Site 0010) | Houston | Texas | 77030 | Recruiting |
| START Mountain Region ( Site 0008) | West Valley City | Utah | 84119 | Recruiting |
| University of Virginia Health System ( Site 0011) | Charlottesville | Virginia | 22908 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06843447, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 12, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06843447 live on ClinicalTrials.gov.